Conscious Sedation for Dilatation and Curettage: Remifentanil Combined with Low-dose Propofol'

Remifentanil Used for Conscious Sedation for Dilatation and Curettage under BIS

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPC-15005822

Enrollment

Unknown

Registered

2014-04-04

Start date

2014-04-05

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spontaneous abortion

Interventions

satisfied:decrease remifentanil by a step of 0.2ng/ml

unsatisfied:increase remifentanil by a step of 0.2ng/ml

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. ASA I~II. 18~45years old; 2. sign the agreement, accept the method, volunteer to be in the study

Exclusion criteria

Exclusion criteria: 1. difficult airway; 2. history of chronic respiratory disease such as chronic obstructive pulmonary disease or asthma; 3. recent respiratory tract infection; 4. current smokers; 5. clinically significant cardiovascular, hepatic, or renal disease.

Design outcomes

Primary

Measure	Time frame
Observer's Assessment of Alerrtness/sedation;	—

Secondary

Measure	Time frame
The time from drug infusion discontinuation to eyes opening;Adverse events in circulation and respiration;	—

Contacts

Public ContactRong Yang

1227875407@qq.com+86 13067904291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026